2021 BQ Journal Vol 42 - 25

Early Release

vaccination opportunities at or close to the workplace. State
and local health authorities will need to take local COVID-19
epidemiology and demand for vaccine into account when
deciding to proceed to the next phase or to subprioritize
within an allocation phase if necessary. A flexible approach to
allocation will facilitate efficient management and ensure that
COVID-19 vaccine is administered equitably and without
delay. Additional interim considerations for phased implementation of COVID-19 vaccines are available at https://www.cdc.
gov/vaccines/covid-19/initial-populations.html and https://
www.cdc.gov/vaccines/covid-19/phased-implementation.html.

Health, University of Maryland School of Medicine; Sean O'Leary,
American Academy of Pediatrics; Christine Oshansky, Biomedical
Advanced Research and Development Authority; Stanley Perlman,
Department of Microbiology and Immunology, University of Iowa;
Marcus Plescia, Association of State and Territorial Health Officials;
Chris Roberts, National Institutes of Health; William Schaffner,
National Foundation for Infectious Diseases; Rob Schechter,
Association of Immunization Managers; Kenneth Schmader,
American Geriatrics Society; Bryan Schumacher, Department of
Defense; Jonathan Temte, American Academy of Family Physicians;
Matthew Tunis, National Advisory Committee on Immunization
Secretariat, Public Health Agency of Canada; Thomas Weiser, Indian
Health Service; Matt Zahn, National Association of County and City
Health Officials; Rachel Zhang, Food and Drug Administration.

Phase 2
Phase 2 includes all other persons aged ≥16 years not
already recommended for vaccination in Phases 1a, 1b, or 1c.
Currently, in accordance with recommended age and conditions of use (1), any authorized COVID-19 vaccine may be
used. ACIP is closely monitoring clinical trials in children
and adolescents and will consider recommendations for use
when a COVID-19 vaccine is authorized for use in persons
aged <16 years.

Corresponding author: Kathleen Dooling, vic9@cdc.gov.
1CDC COVID-19 Response Team; 2Epidemic Intelligence Service, CDC;
3General Dynamics Information Technology, Falls Church, Virginia; 4Stanford
University School of Medicine, Stanford, California; 5Vanderbilt University
School of Medicine, Nashville, Tennessee; 6Arkansas Department of Health;
7University of Washington, Seattle, Washington.

All authors have completed and submitted the International
Committee of Medical Journal Editors form for disclosure of potential
conflicts of interest. No potential conflicts of interest were disclosed.

Acknowledgments

References

Voting members of the Advisory Committee on Immunization
Practices: Robert L. Atmar, Baylor College of Medicine; Kevin A.
Ault, University of Kansas Medical Center; Lynn Bahta, Minnesota
Department of Health; Henry Bernstein, Zucker School of Medicine
at Hofstra/Northwell Cohen Children's Medical Center; Sharon E.
Frey, Saint Louis University Medical School; Paul Hunter, City of
Milwaukee Health Department; Veronica V. McNally, Franny Strong
Foundation; Katherine A. Poehling, Wake Forest School of Medicine;
Pablo J. Sanchez, The Research Institute at Nationwide Children's
Hospital; Peter Szilagyi, University of California, Los Angeles.
Members of the Advisory Committee on Immunization Practices
COVID-19 Vaccines Work Group: Edward Belongia, Center for
Clinical Epidemiology & Population Health, Marshfield Clinic
Research Institute; Dayna Bowen Matthew, George Washington
University Law School; Oliver Brooks, National Medical Association;
Matthew Daley, Institute for Health Research, Kaiser Permanente
Colorado; Jillian Doss-Walker, Indian Health Service; Marci Drees,
Society for Healthcare Epidemiology of America; Jeffrey Duchin,
Infectious Diseases Society of America; Doran Fink, Food and Drug
Administration; Sandra Fryhofer, American Medical Association;
Jason M. Goldman, American College of Physicians; Michael Hogue,
American Pharmacists Association; Denise Jamieson, American
College of Obstetricians and Gynecologists; Jeffery Kelman,
Centers for Medicare & Medicaid; David Kim, U.S. Department
of Health and Human Services; Kathy Kinlaw, Center for Ethics,
Emory University; Susan Lett, Council of State and Territorial
Epidemiologists; Kendra McMillan, American Nurses Association;
Kathleen Neuzil, Center for Vaccine Development and Global

1. Food and Drug Administration. COVID-19 vaccines. Silver Spring,
MD: US Department of Health and Human Services, Food and
Drug Administration; 2020. https://www.fda.gov/emergencypreparedness-and-response/coronavirus-disease-2019-covid-19/
covid-19-vaccines
2. Dooling K, McClung N, Chamberland M, et al. The Advisory
Committee on Immunization Practices' interim recommendation for
allocating initial supplies of COVID-19 vaccine-United States, 2020.
MMWR Morb Mortal Wkly Rep 2020;69:1857-9. PMID:33301429
https://doi.org/10.15585/mmwr.mm6949e1
3. Cybersecurity and Infrastructure Security Agency. Guidance on
essential critical infrastructure workers: version 4.0. Washington,
DC: US Department of Homeland Security, Cybersecurity and
Infrastructure Security Agency; 2020. https://www.cisa.gov/publication/
guidance-essential-critical-infrastructure-workforce
4. National Academies of Sciences, Engineering, and Medicine. Framework
for equitable allocation of COVID-19 vaccine. Washington, DC: National
Academies of Sciences, Engineering, and Medicine; 2020. https://www.
nationalacademies.org/our-work/a-framework-for-equitable-allocationof-vaccine-for-the-novel-coronavirus#sectionPublications
5. Bui DP, McCaffrey K, Friedrichs M, et al. Racial and ethnic disparities
among COVID-19 cases in workplace outbreaks by industry sector-
Utah, March 6-June 5, 2020. MMWR Morb Mortal Wkly Rep
2020;69:1133-8. PMID:32817604 https://doi.org/10.15585/mmwr.
mm6933e3
6. Waltenburg MA, Victoroff T, Rose CE, et al.; COVID-19 Response
Team. Update: COVID-19 among workers in meat and poultry
processing facilities-United States, April-May 2020. MMWR Morb
Mortal Wkly Rep 2020;69:887-92. PMID:32644986 https://doi.
org/10.15585/mmwr.mm6927e2
7. CDC. Coronavirus disease 2019 (COVID-19): CDC COVID data
tracker. Atlanta, GA: US Department of Health and Human Services,
CDC; 2020. https://covid.cdc.gov/covid-data-tracker

MMWR / December 22, 2020 / Vol. 69

Diagnostics I Pharmaceuticals I DxRx Solutions I Continuing Education I News
25

A Henry Schein Publication

https://www.cdc.gov/vaccines/covid-19/initial-populations.html https://www.cdc.gov/vaccines/covid-19/initial-populations.html https://www.cdc.gov/vaccines/covid-19/phased-implementation.html https://www.cdc.gov/vaccines/covid-19/phased-implementation.html https://www.fda.gov/emergency-preparedness-and-response/coronavirus-disease-2019-covid-19/covid-19-vaccines https://www.fda.gov/emergency-preparedness-and-response/coronavirus-disease-2019-covid-19/covid-19-vaccines https://www.fda.gov/emergency-preparedness-and-response/coronavirus-disease-2019-covid-19/covid-19-vaccines https://www.doi.org/10.15585/mmwr.mm6949e1 https://www.cisa.gov/publication/guidance-essential-critical-infrastructure-workforce https://www.cisa.gov/publication/guidance-essential-critical-infrastructure-workforce https://www.nationalacademies.org/our-work/a-framework-for-equitable-allocation-of-vaccine-for-the-novel-coronavirus#sectionPublications https://www.nationalacademies.org/our-work/a-framework-for-equitable-allocation-of-vaccine-for-the-novel-coronavirus#sectionPublications https://www.nationalacademies.org/our-work/a-framework-for-equitable-allocation-of-vaccine-for-the-novel-coronavirus#sectionPublications https://doi.org/10.15585/mmwr.mm6933e3 https://doi.org/10.15585/mmwr.mm6933e3 https://doi https://covid.cdc.gov/covid-data-tracker

2021 BQ Journal Vol 42

Table of Contents for the Digital Edition of 2021 BQ Journal Vol 42